(271 days)
The ABX MICROS ES 60 (OT and CT models) is a quantitative multi-parameter, automated hematology analyzer for in vitro diagnostic use in clinical laboratories to identify and enumerate the following parameters: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, LYM%, LYM#, MON%, MON#, GRA%, GRA#, in K2EDTA and K3EDTA anticoagulated venous whole blood samples of adult patients and pediatric patients ≥ 1 month of age.
The ABX MICROS ES 60 is an automated hematology analyzer developed by HORIBA Medical and cleared under K141161. No modification (hardware or software) to the ABX MICROS ES 60 cleared device (K141161) was made to support the pediatric claim addition. Performance verification has been done to support the pediatric claim addition. The corresponding User Instructions for Use was updated to include this additional claim to the intended use.
The document describes the ABX MICROS ES 60, an automated hematology analyzer, and the studies conducted to support its expanded use for pediatric patients (≥ 1 month of age).
Here's the breakdown of the acceptance criteria and the study that proves the device meets them:
1. Table of Acceptance Criteria and Reported Device Performance
The document primarily focuses on comparability with a predicate device and reference interval validation for the pediatric claim. Specific quantitative acceptance criteria are indirectly implied by the "Bias was estimated at various data points, particularly around medical decision points, for each parameter. Bias was estimated for one replicate. Acceptance criteria were met for all measurands at all levels, except for RDW" statement. While the exact numerical acceptance limits for bias are not explicitly listed in a table, the document states they were met for all measured parameters except RDW.
For the Reference Interval, the acceptance criteria were that the results obtained from normal pediatric samples on the ABX MICROS ES 60 should fall within established pediatric reference ranges.
| Parameter | Acceptance Criteria (Implicit: Minimal Bias vs. Predicate) | Reported Device Performance |
|---|---|---|
| WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, LYM%, LYM#, MON%, MON#, GRA%, GRA# | Bias around medical decision points was within acceptable limits when compared to the predicate device. | Acceptance criteria were met for all measurands at all levels, except for RDW (due to different calculation methods). |
| Parameter (Reference Intervals for Pediatrics) | Acceptance Criteria (Results within Published Ranges) | Reported Device Performance (Table of Reference Ranges) |
|---|---|---|
| WBC, RBC, HGB, HCT, MCV, RDW, MCH, MCHC, PLT, MPV, LYM#, LYM%, MON#, MON%, GRA#, GRA% | Results from normal pediatric samples on ABX MICROS ES 60 fall within established pediatric reference ranges. | Combined Pediatric Reference Ranges (as given in the document) |
2. Sample Size Used for the Test Set and Data Provenance
-
Comparability Study (Bias Estimation):
- Sample Size: 137 venous whole blood specimens.
- Age Range: Pediatric patients between 1 month and 21 years of age.
- Data Provenance: The study was conducted at two test sites in the US and one test site in France. This indicates a prospective study design, collecting samples specifically for the evaluation.
-
Reference Interval Study:
- Sample Size: 69 normal pediatric samples (37 female and 32 male).
- Age Range: Not explicitly stated for all, but categorized into 1m-2y, >2y-12y, and >12y-21y.
- Data Provenance: Performed at one test site in the US. This also suggests a prospective collection of samples from normal pediatric patients.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications
The document does not mention the use of experts to establish ground truth for the test set.
- In the comparability study, the predicate device (Sysmex XN Series, XN-10) served as the reference standard for comparison. The performance of the predicate device is assumed to be the "ground truth" or accepted standard for those measurements.
- In the reference interval study, previously published pediatric reference ranges from several US hospitals were used as the "ground truth" for expected normal values.
Since this is an automated hematology analyzer measuring quantitative parameters, ground truth is typically established by comparison to other validated methods or established reference intervals, rather than by expert interpretation of images or data.
4. Adjudication Method for the Test Set
Not applicable, as expert adjudication (e.g., 2+1, 3+1) is specific to studies where human interpretation is involved in establishing ground truth, such as in image analysis or differential cell counts performed manually. For automated quantitative measurements, the comparison is typically against a reference method or validated ranges.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study was done
No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. These studies are typically performed to assess the impact of AI on human reader performance, usually in diagnostic imaging. This document describes the validation of an automated hematology analyzer, which does not involve human readers interpreting AI output.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) was done
Yes, the studies described are standalone performance evaluations. The ABX MICROS ES 60 is an automated hematology analyzer, meaning it operates without direct human intervention in the measurement and parameter calculation process. The studies assessed the device's performance directly against a predicate device and established reference ranges.
7. The Type of Ground Truth Used
- For the comparability study (bias estimation): The Sysmex XN Series, XN-10 (K112605) predicate device served as the reference for comparison. The measurements from this established device were considered the "ground truth" for assessing bias.
- For the reference interval study: Published pediatric reference ranges obtained from several US hospitals were used as the ground truth.
8. The Sample Size for the Training Set
The document does not describe a "training set" in the context of machine learning, as the ABX MICROS ES 60 is an automated analyzer based on physical principles (impedance, spectrophotometry) rather than a machine learning algorithm that is "trained" on data. The device was previously cleared under K141161, and this submission is for an additional pediatric claim without hardware or software modification to the cleared device. Therefore, no new training set or training process for the algorithm is described for this specific submission.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no mention of a "training set" for a machine learning algorithm in this 510(k) submission. The device operates based on established physical principles and its original validation (K141161) would have involved standard analytical validation studies.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image contains the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
November 01, 2017
HORIBA ABX SAS Caroline Ferrer Regulatory Affairs Manager Parc Euromedecine Rue du Caducee BP 7290 34184 Montpellier Cedex 4 - France
Re: K170353
Trade/Device Name: ABX MICROS ES 60 OT and ABX MICROS ES 60 CT Regulation Number: 21 CFR 864.5220 Regulation Name: Automated differential cell counter Regulatory Class: Class II Product Code: GKZ Dated: September 28, 2017 Received: October 2, 2017
Dear Caroline Ferrer:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR
{1}------------------------------------------------
803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely.
Leonthena R. Carrington -S
Lea Carrington Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration
Indications for Use
510(k) Number (if known) K170353
Device Name
ABX MICROS ES 60 OT (Open Tube model) ABX MICROS ES 60 CT (Close Tube model)
Indications for Use (Describe)
The ABX MICROS ES 60 (OT and CT models) is a quantitative multi-parameter, automated hematology analyzer for in vitro diagnostic use in clinical laboratories to identify and enumerate the following parameters: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, LYM%, LYM#, MON%, MON#, GRA%, GRA#, in K2EDTA and K3EDTA anticoagulated venous whole blood samples of adult patients and pediatric patients ≥ 1 month of age.
| Type of Use (Select one or both, as applicable) | ☑ Prescription Use (Part 21 CFR 801 Subpart D) ☐ Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| ------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the
time to review instructions, search existing data sources, gather and maintain the data needed and complete
and review the collection of information. Send comments regarding this burden estimate or any other aspect
of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services
Food and Drug Administration
Office of Chief Information Officer
Paperwork Reduction Act (PRA) Staff
PRAStaff@fda.hhs.gov"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
Premarket Notification [510(k)] Summary
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is : K170353
1.0 Submitted bv : Company: HORIBA ABX SAS HORIBA MEDICAL Parc Euromédecine Rue du Caducée - BP 7290 34184 Montpellier cedex 4 FRANCE
Contact Person: Caroline FERRER Telephone (France): +33 467 141843 Email: caroline.ferrer@horiba.com
Date Submitted : 2.0
28th September 2017
3.0 Device Name and Classification : ABX MICROS ES 60 Trade/Proprietary Name:
Classification:
Device: Counter, differential cell Panel: 81 Hematology Regulation number: 864.5220 Product Code: GKZ Class: 2
4.0 System description : 4.1 Device Description
The ABX MICROS ES 60 is an automated hematology analyzer developed by HORIBA Medical and cleared under K141161.
No modification (hardware or software) to the ABX MICROS ES 60 cleared device (K141161) was made to support the pediatric claim addition.
Performance verification has been done to support the pediatric claim addition.
{4}------------------------------------------------
The corresponding User Instructions for Use was updated to include this additional claim to the intended use.
4.2 Principles of Operation
The ABX MICROS ES 60 performs hematology analyses using the following methods:
- RBC / PLT: Impedance ●
- WBC: Impedance ●
- HGB: Spectrophotometry
- DIFF: Impedance ●
The Principles of Operation are unchanged.
4.3 Modes of Operation
Two models of ABX MICROS ES 60 are available.
The Closed Tube (CT) instrument: it has a cap-piercing mechanism. The blood collection tube ● is placed directly in the analyzer without removing the cap.
. The Open Tube (OT) instrument: the cap form the blood collection tube must be removed before analyzing the sample.
4.4 Specimen Identification
Specimen identification is by manual sample identification with the use of a hand held barcode scanner.
4.5 Calibration
Calibration is a procedure that is performed during specific situations such as installation, maintenance or service intervention. It is performed by a HORIBA ABX SAS representative. It ensures that the precision and accuracy of the analyzer are acceptable, so that accurate measurements are performed by the analyzer.
There is no specific calibrator for pediatric addition.
{5}------------------------------------------------
4.6 Quality Control
Quality control allows the user to monitor a set of analyses based on known sample values and ranges over a period of several months. Statistical computation performed on these populations allows the extraction of qualitative information related to the stability of the instrument.
The manufacturer's instructions are to be followed for material and frequency of quality control analysis.
There is no specific control for pediatric addition.
4.7 Software
FDA has reviewed HORIBA ABX SAS's Hazard Analysis and Software Development processes for this line of product types during the 510(k) file K141161 review.
No change was made to the Hazard Analysis and Software Development processes relative to the pediatric use addition.
5.0 Intended use
5.1 Indications for Use :
The ABX MICROS ES 60 (OT and CT models) is a quantitative multi-parameter, automated hematology analyzer for in vitro diagnostic use in clinical laboratories to identify and enumerate the following parameters: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, LYM%, LYM#, MON%, MON#, GRA%, GRA#, in K2EDTA and K3EDTA anticoagulated venous whole blood samples of adult patients and pediatric patients > 1 month of age.
5.2 Special Conditions for Use Statements:
For prescription use only
{6}------------------------------------------------
6.0 Comparison with the original device :
Similarities
| Item | ABX MICROS ES 60Device with additional pediatricintended use | ABX MICROS ES 60 (K141161)Previous Device |
|---|---|---|
| Manufacturer | HORIBA ABX SAS | HORIBA ABX SAS |
| Type of product | Automated blood cell counter | Automated blood cell counter |
| Parameters | Complete Blood Cell Count (CBC)WBC, RBC, HGB, HCT, MCV,MCH, MCHC, RDW, PLT, MPV | Complete Blood Cell Count (CBC)Same |
| Leukocyte Differential (DIFF):LYM (# and %), MON (# and %),GRA (# and %) | Leukocyte Differential (DIFF):Same | |
| Sample types | K2 and K3EDTA anti-coagulatedwhole blood | Same |
| Principles ofmeasurements | RBC / PLT: ImpedanceWBC / DIFF: ImpedanceHGB: SpectrophotometryRDW, MCV, MCH, MCHC:Calculation | Same |
| Reagents | ABX Minidil LMGABX Minilyse LMG or ABXAlphalyse 360ABX MinicleanABX Minipack LMGABX Minoclair | Same |
| Calibrators | ABX Minocal | Same |
| Controls | ABX Minotrol 16 (3 levels) | Same |
| Throughput | OT / CT models: 60 / 50 samples perhour | Same |
| Dimensions(Height x Width xDepth) | 43 cm x 36 cm x 36 cm | Same |
{7}------------------------------------------------
Differences
| Item | ABX MICROS ES 60Device with additional pediatricintended use | ABX MICROS ES 60 (K141161)Previous Device |
|---|---|---|
| Intended Use | The ABX MICROS ES 60 (OT and CTmodels) is a quantitative multi-parameter, automated hematologyanalyzer for in vitro diagnostic use inclinical laboratories to identify andenumerate the following parameters:WBC, RBC, HGB, HCT, MCV, MCH,MCHC, RDW, PLT, MPV, LYM%,LYM#, MON%, MON#, GRA%,GRA#, in K2EDTA and K3EDTAanticoagulated venous whole bloodsamples of adult patients and pediatricpatients ≥ 1 month of age. | Same except:- sample type was venous only- intended population was adultpatients only. |
{8}------------------------------------------------
7.0 Substantial Equivalence Information :
The following tables show the similarities and differences between the candidate device and its predicate device identified below.
7.1 Predicate Device Name and 510(k) number:
For the validation of the pediatric use on the ABX MICROS ES 60 the following predicate device was used during the clinical evaluation:
| Candidate device | Predicate device | Manufacturer | Predicate 510(k) number |
|---|---|---|---|
| ABX MICROS ES 60 | Sysmex XN Series, XN-10 | SYSMEX | K112605 |
7.2 Comparison with predicate Device : Similarities
| Item | ABX MICROS ES 60 (K141161)Candidate device | Sysmex XN Series, XN-10(K112605)Predicate Device |
|---|---|---|
| Manufacturer | HORIBA ABX SAS | Sysmex |
| Type of product | Automated blood cell counter | Automated blood cell counter |
| Parameters | Complete Blood Cell Count (CBC)WBC, RBC, HGB, HCT, MCV,MCH, MCHC, RDW, PLT, MPVLeukocyte Differential (DIFF):LYM (% and #) | Complete Blood Cell Count (CBC)WBC, RBC, HGB, HCT, MCV,MCH, MCHC, RDW-CV, PLT,MPVLeukocyte Differential (DIFF):LYM (# and %), |
| Sample types | K2 and K3EDTA anti-coagulatedvenous samples | K2 and K3EDTA anti-coagulatedwhole blood |
| Principles ofmeasurements | RBC / PLT: ImpedanceHGB: Spectrophotometry | RBC: Impedance (Sheath Flow)HGB: Spectrophotometry |
| Item | ABX MICROS ES 60 (K141161) Candidate device | Sysmex XN Series, XN-10 (K112605) Predicate Device |
| Intended Use | The ABX MICROS ES 60 (OT and CT models) is a quantitative multi-parameter, automated hematology analyzer for in vitro diagnostic use in clinical laboratories to identify and enumerate the following parameters: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW, PLT, MPV, LYM%, LYM#, MON%, MON#, GRA%, GRA#, in K2EDTA and K3EDTA anticoagulated venous whole blood samples of adult patients and pediatric patients ≥ 1 month of age. | The Sysmex® XN-10 and XN-20 modules are quantitative multi-parameter automated hematology analyzers intended for in vitro diagnostic use in screening patient populations found in clinical laboratories. The XN-Series modules classify and enumerate the following parameters: WBC, RBC, HGB, HCT, MCV, MCH, MCHC, RDW-CV, RDW-SD, PLT, NEUT%/#, LYMPH%/#, MONO%/#, EO%/#, BASO%/#, NRBC%/#, IG%/#, , MPV, RET%/#, IRF, IPF, RET-He |
| Parameters | Leukocyte Differential (DIFF):MON (% and #)GRA (% and #)RDW-SD, NRBC%/#, IG%/#, , MPV, RET%/#, IRF, IPF, RET-He: parameters not available | Leukocyte Differential (DIFF):NEUT%/#ΜΟΝΟ%/#,EO%/#,BASO%/#RDW-SD, NRBC%/#, IG%/#, , MPV, RET%/#, IRF, IPF, RET-He |
| MinimumSampleVolume | 50 µL | Sampler Mode – 88 µLManual (Closed Cap) Mode – 88 µLManual (Open Cap) Mode – 88 µLDilution Mode – 70 µL |
| Specimensample volume | 10 µL | |
| Dimensions | OT / CT models:43 x 36 x 36 cm | 85.5 cm x 64.5 cm x 75.5 cm |
| Weight | OT model: 14 kgCT model: 17 kg | 57 kg |
| Throughput | OT / CT models: 60 / 50 samples per hour | 100 samples/hour maximum depending on mode used. |
| Modes ofOperation | Open Tube ModeClosed Tube Mode | Sampler Analysis ModeManual Closed Analysis ModePre-dilute Analysis Mode Dilute sample 1:7 |
| Principles of Measurement | ||
| WBC, WBCDifferential | Impedance | WBC: Radio-frequency (RF) / Direct-current (DC) Detection Method Flow |
| Item | ABX MICROS ES 60 (K141161)Candidate device | Sysmex XN Series, XN-10 (K112605)Predicate Device |
| (LYM, MON,GRA) | Cytometry Methods using a Semiconductor LaserParticle characterization and identification isbased on detection of forward scatter,fluorescence and adaptive cluster analysis.The XN-Series analyzers automaticallyclassify cells from whole blood | |
| Calibrator | ABX Minocal | XN CAL (XN-10/XN-20 Calibrator)XN CAL PF (Platelet F Calibrator) |
| QualityControls | ABX Minotrol 16(3 levels) | XN-Check - 3 Levels |
| Reagents | ABX Minidil LMG (Diluent)ABX Minilyse LMG or ABX Alphalyse360 (Lyse)ABX Miniclean (Cleaner)ABX Minoclair (Concentrated cleaningreagent)ABX Minipack LMG (Reagent Pack) | CELLPACKTM DCL (Diluent)CELLPACKTM DFL (Diluent)LYSERCELL WNR (Lyse) LYSERCELLWDF (Lyse) LYSERCELL WPC (Lyse)FLUOROCELL WNR (Stain)FLUOROCELL WDF (Stain)FLUOROCELL RET (Stain)FLUOROCELL PLT (Stain)FLUOROCELL WPC (Stain) |
{9}------------------------------------------------
7.3 Comparison with predicate Device : Differences
{10}------------------------------------------------
8.0 Special Control/Guidance Document Referenced :
8.1 Standards Followed
- CLSI EP09-A3: Measurement Procedure Comparison and Bias Estimation Using ● Patient Samples - 2013
- CLSI EP28-A3: Defining, Establishing and Verifying Reference Intervals in the ● Clinical Laboratory - 2008
8.2 FDA Guidances Followed
- Guidance for Industry and FDA Staff : Format for Traditional and Abbreviated 510(k)s ● - 2005
- Final Guidance for Industry and FDA: Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells - 2001
{11}------------------------------------------------
9.0 Summary of Performance Data :
9.1 Comparability with Predicate Device
A total of 137 venous whole blood specimens (collected in K2EDTA) from pediatric patients between 1 month and 21 years of age were collected and analyzed at two test sites in the US and one test site in France. Different instruments and operators were used at each site.
Each of the samples was analyzed in duplicate on the ABX MICROS ES 60 and once on the predicate XN Series, XN-10 from SYSMEX.
Bias was estimated at various data points, particularly around medical decision points, for each parameter. Bias was estimated for one replicate. Acceptance criteria were met for all measurands at all levels, except for RDW, due to the difference of calculation methods on the two analyzers. These findings support the claim that the ABX MICROS ES 60 candidate device and the XN Series, XN-10 predicate device are substantially equivalent, and demonstrate acceptable levels of bias for pediatric samples.
9.2 Reference Interval
69 (37 female and 32 male) normal pediatric samples (whole blood samples collected in K2EDTA) were analyzed, when possible in duplicate, on the ABX MICROS ES 60 at one test site in the US. Results were compared to a pediatric reference range obtained from several US hospitals published ranges. Results were contained in the pediatric reference range, confirming the transference of the pediatric reference range below for the ABX MICROS ES 60:
| Combined Pediatric | MALE | FEMALE | |||||
|---|---|---|---|---|---|---|---|
| Reference Range parameters | 1 m - 2 y | >2y - 12 y | >12 y - 21 y | 1 m - 2 y | >2y - 12 y | >12 y - 21 y | |
| WBC | (10³/mm³) | 5.0 - 20.0 | 3.4 - 17.0 | 3.5 - 13.0 | 5.0 - 20.0 | 3.4 - 17.0 | 3.5 - 13.0 |
| RBC | (10⁶/mm³) | 2.7 - 6.0 | 3.9 - 5.5 | 4.0 - 5.7 | 2.7 - 6.0 | 3.8 - 5.5 | 3.7 - 5.2 |
| HGB | g/dL | 8.9 - 18.0 | 10.2 - 15.5 | 11.0 - 18.0 | 9.0 - 18.0 | 10.2 - 15.5 | 10.6 - 16.0 |
| HCT | % | 28.0 - 55.0 | 31.0 - 45.0 | 33.9 - 49.0 | 27.7 - 55.0 | 31.0 - 45.0 | 32.9 - 49.0 |
| MCV | μm³ | 70 - 123 | 70 - 95 | 77 - 102 | 70 - 123 | 70 - 95 | 76.9 - 102 |
| RDW | % | 11.0 - 16.5 | 11.0 - 16.0 | 11.0 - 15.6 | 11.0 - 16.5 | 11.0 - 16.0 | 11.0 - 15.5 |
| MCH | pg | 22.7 - 36.0 | 23.0 - 33.0 | 25.0 - 35.0 | 24.4 - 35 | 23.7 - 33.0 | 24.8 - 35.0 |
| MCHC | % | 28 - 37 | 30 - 37 | 31 - 37 | 28 - 36 | 30 - 37 | 31 - 37 |
| PLT | (10³/mm³) | 140 - 562 | 140 - 450 | 140 - 450 | 140 - 597 | 140 - 450 | 140 - 450 |
| MPV | μm³ | 6.5 - 12.4 | 6.5 - 12.4 | 6.5 - 12.4 | 6.5 - 12.4 | 6.5 - 12.4 | 6.5 - 12.4 |
| LYM# | (10³/mm³) | 1.50 - 16.50 | 0.97 - 10.50 | 0.85 - 6.50 | 1.50 - 16.50 | 1.16 - 10.50 | 0.90 - 6.50 |
| LYM% | % | 26 - 86 | 15 - 75 | 12 - 53 | 27 - 87 | 17 - 75 | 13 - 50 |
| MON# | (10³/mm³) | 0.00 - 1.40 | 0.00 - 1.00 | 0.00 - 0.90 | 0.00 - 1.40 | 0.00 - 1.00 | 0.00 - 0.90 |
| MON% | % | 0 - 14 | 0 - 12 | 0 - 13 | 0 - 13 | 0 - 12 | 0 - 13 |
| GRA# | (10³/mm³) | 0.84 - 10.1 | 1.50 - 9.45 | 1.50 - 8.80 | 1.01 - 10.45 | 1.50 - 9.45 | 1.50 - 8.80 |
| GRA% | % | 10 - 80 | 12 - 85 | 31 - 87 | 9 - 86 | 12 - 81 | 31 - 87 |
These intervals are given in the labeling of the ABX MICROS ES 60.
However, expected values will vary with sample population and/or geographical location. HORIBA highly recommends that each laboratory establishes its own normal ranges based upon its local population.
{12}------------------------------------------------
10.0 Proposed Labeling :
The labeling is written as per the recommendations given in standard EN18113-2. It takes into account the requirements of 21 CFR Part 809.10.
11.0 Conclusion :
As per 21CFR Part §807.92(b)(3), the nonclinical tests demonstrate that the ABX MICROS ES 60 device is as safe, as effective, and performs as well as or better than the predicate device for pediatric population (≥1 month of age).
The submitted information in this premarket notification is complete and supports a substantial equivalence decision on pediatric use addition.
§ 864.5220 Automated differential cell counter.
(a)
Identification. An automated differential cell counter is a device used to identify one or more of the formed elements of the blood. The device may also have the capability to flag, count, or classify immature or abnormal hematopoietic cells of the blood, bone marrow, or other body fluids. These devices may combine an electronic particle counting method, optical method, or a flow cytometric method utilizing monoclonal CD (cluster designation) markers. The device includes accessory CD markers.(b)
Classification. Class II (special controls). The special control for this device is the FDA document entitled “Class II Special Controls Guidance Document: Premarket Notifications for Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA.”